BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

  << Back  |   Print
 
Eisai Presents New Quality of Life Findings in Patients with Metastatic Breast Cancer from Halaven(R) (Eribulin) versus Capecitabine Study at 49th ASCO Annual Meeting

Tokyo, June 3, 2013 - (JCN Newswire) - Eisai Co., Ltd. announced today at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) new findings showing that Halaven(R) (eribulin mesylate, "eribulin") improved overall quality of life (QOL) (Global Health Status and QOL, "GHS/QOL") significantly more than capecitabine over the course of a Phase III study (Study 301) in patients with metastatic breast cancer who had been previously treated with anthracyclines and taxanes.

The findings presented were based on an analysis of responses to questions on QOL related to the symptoms, functioning, and overall well-being of those patients who participated as subjects in Study 301. The GHS/QOL score results, which indicate overall patient QOL, were shown to improve significantly more for patients administered eribulin versus capecitabine (p=0.048) over the course of treatment. Eribulin also performed significantly better than capecitabine in assessments of cognitive functioning (p<0.001), nausea and vomiting (p=0.043), and diarrhea (p=0.001). In comparison, capecitabine performed significantly better compared to eribulin in evaluations of emotional functioning (p=0.033), systemic side effects (p<0.001), and upset by hair loss (p=0.023).

Cancer and its treatment have a major impact on patient QOL such as difficulties with family life and fulfilling family roles, demonstrating ability at work, and participation in common social activities. A central goal in developing novel therapies for patients with metastatic breast cancer is to extend life for as long as possible while ensuring that optimal patient QOL is maintained. Effective QOL management is also important because it allows the treatment to continue, thus enabling the maximum benefits of the treatment to be provided to patients.

All QOL data collected in the study serve to offer a better understanding on how the QOL of patients with breast cancer may be affected by either treatment, and Eisai believes that the findings will serve as a valuable reference for making informed decisions when considering which treatment to undergo. The company remains committed to providing further clinical evidence for eribulin aimed at maximizing value of the drug as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

For more information, please see http://www.eisai.com/news/news201334.html.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:

Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
 
June 3, 2013
Source: Eisai

Eisai (TSE: 4523) (U.S: ESALY)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary